Recent Updates
Recently added Catalysts
SPTX Positive Sentiment

Seaport Therapeutics to Participate in Upcoming Investor Conferences

Key Takeaway: Seaport Therapeutics announced its participation in upcoming investor conferences, including the Oppenheimer Private Life Sciences Company Showcase and the 5th Annual Needham Private Biotech and MedTech Company Forum. The management team will present and engage in one-on-one meetings with investors. The company focuses on developing novel neuropsychiatric medicines using its proprietary Glyph technology platform.

Market Sentiment Analysis

POSITIVE FACTORS

  • Seaport Therapeutics is advancing novel neuropsychiatric medicines.
  • The company has a proven strategy and experienced management team.
  • Participation in multiple investor conferences indicates strong investor interest.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Low dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)

Full Press Release Details

Boston, MA – September 18, 2025 – Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that members of its management team will participate in the following upcoming investor conferences:
• Oppenheimer Private Life Sciences Company Showcase The management team will present on Thursday, September 25, 2025,at 11:45 AM – 12:05 PM EDT. The Company will also participate in one-on-one meetings at the conference. The live and archived webcast will be available under the Events section of the Seaport website at https://seaporttx.com/news-papers/ .
• The management team will present on Thursday, September 25, 2025,at 11:45 AM – 12:05 PM EDT. The Company will also participate in one-on-one meetings at the conference. The live and archived webcast will be available under the Events section of the Seaport website at https://seaporttx.com/news-papers/ .
• 5 th Annual Needham Private Biotech and MedTech Company Forum The Company will participate in one-on-one meetings during the conference on October 14 – 15, 2025.
• The Company will participate in one-on-one meetings during the conference on October 14 – 15, 2025.
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians, and key opinion leaders. For more information, please visit www.seaporttx.com .

Frequently Asked Questions

What conferences will Seaport Therapeutics attend?

Seaport Therapeutics will attend the Oppenheimer Private Life Sciences Company Showcase and the 5th Annual Needham Private Biotech and MedTech Company Forum.

When is Seaport's presentation at the Oppenheimer conference?

Seaport's presentation at the Oppenheimer conference is scheduled for September 25, 2025, from 11:45 AM to 12:05 PM EDT.

What is the focus of Seaport Therapeutics?

Seaport Therapeutics focuses on advancing novel neuropsychiatric medicines using its proprietary Glyph technology platform.

How can investors access Seaport's conference presentations?

Investors can access live and archived webcasts of Seaport's presentations on their website.

Last updated: Sep 18, 2025